Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Following the cancellation of the subsidiary merger, Alteogen issued this corrective filing to formally cancel its previously announced merger decision between Altos Biologics and Alteogen Healthcare.
📊 [Key Disclosure Details & Financial Highlights]
- Corrected Filing: Decision on Merger (Major Management Matters of Subsidiary) (Original Filing Date: 2024-11-07)
- Reason for Correction: Revocation of merger decision due to the cancellation of the subsidiary merger
- Target Subsidiary: Altos Biologics Corp. (CEO: Hee Jeong Ji, Main Business: Biopharmaceutical R&D, Major Subsidiary: Yes)
- Subsidiary Total Assets: KRW 63.59B (24.83% of parent company’s consolidated total assets of KRW 256.10B)
- Key Correction Details (Cancellation of Merger Terms):
- Target Merger Partner: Alteogen Healthcare Inc. (Dissolved entity) ☞ (After Correction) – (Cancelled)
- Method, Purpose, and Ratio of Merger: All items removed and cancelled
- Number and Type of New Shares to Issue: (Before) Previously projected numbers ☞ (After Correction) – (Cancelled)
- Scheduled Merger Timelines (EGM Date, Creditor Objection Period, Merger Date, Registration Date, etc.): All items removed and cancelled
- Board Resolution Date: (Before Correction) 2024-11-14 ☞ (After Correction) – (Cancelled)
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verification of Corrected Merger Decision Filings Following Cancellation
This filing serves as a formal corrective disclosure replacing the details of the previously announced subsidiary merger decision with cancelled (-) entries due to the merger revocation. Verifying that the cancellation processing of the previous disclosure entries is finalized in the official disclosure database is important to confirm data integrity. The finalized updates can be verified in the corrected disclosure text on DART and upcoming periodic business reports.
📢 Disclaimer & Source Information
Source: This content was structured and generated based on official submission data from the Financial Supervisory Service’s Data Analysis, Retrieval and Transfer System (DART).
Investment Risk Warning: This content is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For inquiries regarding regulatory compliance or copyright requests, please contact ksb220805@gmail.com.
